Skip to content
DraconiticResearch
Search Sources API
197,693 studies31 sourcesUpdated just now
Peer-reviewedLicence not statedClinical cancer research : an official journal of the American Association for Cancer Research

FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma

  • Rachel Ershler1
  • Xueping Zhou1
  • Keng Hee Peh1
  • Hui Wei1
  • Somak Chatterjee1
  • Xiling Jiang1
  • Jiang Liu1
  • Olanrewaju O. Okusanya1
  • Yuan-Li Shen1
  • Natasha Kormanik1
  • Theresa Carioti1
  • R. Angelo de Claro1,2
3 more authors
  • Bindu Kanapuru1
  • Nicole J. Gormley1,2
  • Yvette L. Kasamon1
  1. 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
  2. 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Read full textDOICite

Related

  1. Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
    Yuya Sasaki, Keisuke Tanaka, Hisako Nakamaki +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Synergistic Activity of Venetoclax and Rituximab in Multiply Relapsed or Refractory Waldenström Macroglobulinaemia
    Angeline Josiah, Ryan Low, Alisha Ganesh +5
    EJHaemPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Successful Treatment with Rituximab in a Patient with Clinically Suspected Small-vessel Primary Central Nervous System Vasculitis Refractory to Cyclophosphamide Pulse Therapy
    Takuya Okamoto, Kazuki Yokokawa, Bungo Hirose +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. DURABLE PARTIAL RESPONSE TO EPCORITAMAB IN A MULTIPLY RELAPSED/REFRACTORY ELDERLY PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA: A CASE REPORT
    Valney Oliveira SANTOS JUNIOR, Nelma Carneiro DE ARAUJO, Maura Alice Santos ROMEO +3
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  5. A comparative analysis of semiannual versus annual rituximab maintenance in patients with refractory idiopathic inflammatory myopathies: a retrospective longitudinal real-world study.
    Rodrigo Lorenzetti Serrano, Fernando Henrique Carlos de Souza, Renata Miossi +2
    Revista da Associacao Medica Brasileira (1992)Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ershler2026approval,
  title = {{FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma}},
  author = {Rachel Ershler and Xueping Zhou and Keng Hee Peh and Hui Wei and Somak Chatterjee and Xiling Jiang and Jiang Liu and Olanrewaju O. Okusanya and Yuan-Li Shen and Natasha Kormanik and Theresa Carioti and R. Angelo de Claro and Bindu Kanapuru and Nicole J. Gormley and Yvette L. Kasamon},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  year = {2026},
  month = oct,
  doi = {10.1158/1078-0432.ccr-26-1867},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-1867},
}
RIS
TY  - JOUR
TI  - FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
AU  - Rachel Ershler
AU  - Xueping Zhou
AU  - Keng Hee Peh
AU  - Hui Wei
AU  - Somak Chatterjee
AU  - Xiling Jiang
AU  - Jiang Liu
AU  - Olanrewaju O. Okusanya
AU  - Yuan-Li Shen
AU  - Natasha Kormanik
AU  - Theresa Carioti
AU  - R. Angelo de Claro
AU  - Bindu Kanapuru
AU  - Nicole J. Gormley
AU  - Yvette L. Kasamon
PY  - 2026
DA  - 2026/10/01
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-1867
UR  - https://doi.org/10.1158/1078-0432.ccr-26-1867
SN  - 1078-0432
SN  - 1557-3265
ER  -